Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant

Similar trend of increasing lineage frequency and higher relative Re was also found in USA, Singapore, and Australia (appendix p 13), suggesting that XBB.1.16 could spread worldwide soon. Altogether, our data suggest that XBB.1.16 has a greater growth advantage in the human population compared with...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2023-06, Vol.23 (6), p.655-656
Main Authors: Yamasoba, Daichi, Uriu, Keiya, Plianchaisuk, Arnon, Kosugi, Yusuke, Pan, Lin, Zahradnik, Jiri, Ito, Jumpei, Sato, Kei
Format: Article
Language:English
Subjects:
Consortia
Correspondence
COVID-19
Funding
HIV
Human immunodeficiency virus
Human populations
Humans
Humoral immunity
Infections
Infectious diseases
Infectivity
Medical research
Medical science
Proteins
R&D
Research & development
Research facilities
SARS-CoV-2 - genetics
Science
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Similar trend of increasing lineage frequency and higher relative Re was also found in USA, Singapore, and Australia (appendix p 13), suggesting that XBB.1.16 could spread worldwide soon. Altogether, our data suggest that XBB.1.16 has a greater growth advantage in the human population compared with XBB.1 and XBB.1.5, whereas the ability of XBB.1.16 to exhibit profound immune evasion is similar to XBB.1 and XBB.1.5. Since the spike proteins of XBB.1.16 and XBB.1.5 exhibit similar characteristics in terms of infectivity and escape ability from humoral immunity, the increased fitness of XBB.1.16 might be attributed to the mutations in non-spike proteins. For more on Nextstrain see https://nextstrain.org/ncov/gisaid/global/6m KS reports funding from the Japan Agency for Medical Research and Development (AMED) Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA) Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA programme (JP223fa627001); AMED SCARDA Program on R&D of New Generation Vaccine Including New Modality Application (JP223fa727002); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146, JP21fk0108494, JP21fk0108425, JP21fk0108432, JP22fk0108511, JP22fk0108516, and JP22fk0108506); AMED Research Program on HIV/AIDS (JP22fk0410039); Japan Science and Technology Agency (JST) Core Research for Evolutional Science and Technology (CREST; JPMJCR20H4); Japan Society for the Promotion of Science (JSPS) Core-to-Core Program (Advanced Research Networks; JPJSCCA20190008); and the Cooperative Research Program (Joint Usage/Research Center programme) of the Institute for Life and Medical Sciences at Kyoto University.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(23)00278-5